PureTech Health (LON:PRTC) Insider Sharon Barber-Lui Buys 93,944 Shares of Stock

PureTech Health plc (LON:PRTC) insider Sharon Barber-Lui purchased 93,944 shares of the business’s stock in a transaction that occurred on Wednesday, July 29th. The stock was acquired at an average price of GBX 1 per share, for a total transaction of £939.44.

Sharon Barber-Lui also recently made the following trade(s):

• On Tuesday, July 7th, Sharon Barber-Lui purchased 29,868 shares of PureTech Health stock. The shares were bought at an average cost of GBX 119 per share, with a total value of £35,542.92.

PureTech Health Stock Down 0.4%

Shares of LON:PRTC traded down GBX 0.48 during midday trading on Friday, reaching GBX 119.12. The company had a trading volume of 512,639 shares, compared to its average volume of 1,072,302. The stock has a market capitalization of £289.96 million, a P/E ratio of -2.59 and a beta of 0.79. The stock’s fifty day moving average price is GBX 127.71 and its 200-day moving average price is GBX 126.71. The company has a debt-to-equity ratio of 6.33, a current ratio of 6.59 and a quick ratio of 2.51. PureTech Health plc has a one year low of GBX 104.71 and a one year high of GBX 146.40.

Wall Street Analyst Weigh In

Separately, Peel Hunt reissued a “buy” rating and issued a GBX 508 price objective on shares of PureTech Health in a report on Monday, July 13th. One analyst has rated the stock with a Buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of GBX 508.

PureTech Health Company Profile

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia.